Research ArticleArticle
Open Access
Does Concomitant Methotrexate with Adalimumab Influence Treatment Outcomes in Patients with Psoriatic Arthritis? Data from a Large Observational Study
Frank Behrens, Michaela Koehm, Uta Arndt, Bianca M. Wittig, Gerd Greger, Diamant Thaçi, Eva Scharbatke, Hans-Peter Tony and Harald Burkhardt
The Journal of Rheumatology December 2015, jrheum.141596; DOI: https://doi.org/10.3899/jrheum.141596
Frank Behrens
From the Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main; Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP, Frankfurt am Main; Rheumapraxis Hofheim, Hofheim; AbbVie Deutschland GmbH and Co. KG, Wiesbaden; Comprehensive Center of Inflammation Medicine, University Hospital Schleswig-Holstein Campus, Luebeck; and Schwerpunkt Rheumatologie/Klinische Immunologie Medizinische Klinik und Poliklinik II, Universität Würzburg, Würzburg, Germany. Supported by AbbVie Deutschland GmbH and Co. KG (formerly Abbott GmbH and Co. KG). F. Behrens, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; M. Koehm, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; H. Burkhardt, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; U. Arndt, MD, Rheumapraxis Hofheim; B.M. Wittig, MD, AbbVie Deutschland GmbH and Co. KG; G. Greger, PhD, AbbVie Deutschland GmbH and Co. KG; D. Thaçi, MD, Comprehensive Center of Inflammation Medicine, University Hospital Schleswig-Holstein Campus; E. Scharbatke, MD; H.P. Tony, MD, Schwerpunkt Rheumatologie/Klinische Immunologie Medizinische Klinik und Poliklinik II, Universität Würzburg. Dr. Behrens, Dr. Koehm, Dr. Arndt, Dr. Thaçi, Dr. Scharbatke, Dr. Tony, and Dr. Burkhardt have received speaker’s fees, research funding, or compensation for consultancies or board memberships from AbbVie Deutschland GmbH and Co. KG (formerly Abbott GmbH and Co. KG). Address correspondence to Dr. H. Burkhardt, Division of Rheumatology, Goethe University, Theodor-Stern-Kai 7, D60590 Frankfurt/Main, Germany. E-mail: Harald.Burkhardt@kgu.de. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication September 1, 2015.
Michaela Koehm
From the Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main; Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP, Frankfurt am Main; Rheumapraxis Hofheim, Hofheim; AbbVie Deutschland GmbH and Co. KG, Wiesbaden; Comprehensive Center of Inflammation Medicine, University Hospital Schleswig-Holstein Campus, Luebeck; and Schwerpunkt Rheumatologie/Klinische Immunologie Medizinische Klinik und Poliklinik II, Universität Würzburg, Würzburg, Germany. Supported by AbbVie Deutschland GmbH and Co. KG (formerly Abbott GmbH and Co. KG). F. Behrens, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; M. Koehm, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; H. Burkhardt, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; U. Arndt, MD, Rheumapraxis Hofheim; B.M. Wittig, MD, AbbVie Deutschland GmbH and Co. KG; G. Greger, PhD, AbbVie Deutschland GmbH and Co. KG; D. Thaçi, MD, Comprehensive Center of Inflammation Medicine, University Hospital Schleswig-Holstein Campus; E. Scharbatke, MD; H.P. Tony, MD, Schwerpunkt Rheumatologie/Klinische Immunologie Medizinische Klinik und Poliklinik II, Universität Würzburg. Dr. Behrens, Dr. Koehm, Dr. Arndt, Dr. Thaçi, Dr. Scharbatke, Dr. Tony, and Dr. Burkhardt have received speaker’s fees, research funding, or compensation for consultancies or board memberships from AbbVie Deutschland GmbH and Co. KG (formerly Abbott GmbH and Co. KG). Address correspondence to Dr. H. Burkhardt, Division of Rheumatology, Goethe University, Theodor-Stern-Kai 7, D60590 Frankfurt/Main, Germany. E-mail: Harald.Burkhardt@kgu.de. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication September 1, 2015.
Uta Arndt
From the Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main; Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP, Frankfurt am Main; Rheumapraxis Hofheim, Hofheim; AbbVie Deutschland GmbH and Co. KG, Wiesbaden; Comprehensive Center of Inflammation Medicine, University Hospital Schleswig-Holstein Campus, Luebeck; and Schwerpunkt Rheumatologie/Klinische Immunologie Medizinische Klinik und Poliklinik II, Universität Würzburg, Würzburg, Germany. Supported by AbbVie Deutschland GmbH and Co. KG (formerly Abbott GmbH and Co. KG). F. Behrens, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; M. Koehm, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; H. Burkhardt, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; U. Arndt, MD, Rheumapraxis Hofheim; B.M. Wittig, MD, AbbVie Deutschland GmbH and Co. KG; G. Greger, PhD, AbbVie Deutschland GmbH and Co. KG; D. Thaçi, MD, Comprehensive Center of Inflammation Medicine, University Hospital Schleswig-Holstein Campus; E. Scharbatke, MD; H.P. Tony, MD, Schwerpunkt Rheumatologie/Klinische Immunologie Medizinische Klinik und Poliklinik II, Universität Würzburg. Dr. Behrens, Dr. Koehm, Dr. Arndt, Dr. Thaçi, Dr. Scharbatke, Dr. Tony, and Dr. Burkhardt have received speaker’s fees, research funding, or compensation for consultancies or board memberships from AbbVie Deutschland GmbH and Co. KG (formerly Abbott GmbH and Co. KG). Address correspondence to Dr. H. Burkhardt, Division of Rheumatology, Goethe University, Theodor-Stern-Kai 7, D60590 Frankfurt/Main, Germany. E-mail: Harald.Burkhardt@kgu.de. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication September 1, 2015.
Bianca M. Wittig
From the Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main; Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP, Frankfurt am Main; Rheumapraxis Hofheim, Hofheim; AbbVie Deutschland GmbH and Co. KG, Wiesbaden; Comprehensive Center of Inflammation Medicine, University Hospital Schleswig-Holstein Campus, Luebeck; and Schwerpunkt Rheumatologie/Klinische Immunologie Medizinische Klinik und Poliklinik II, Universität Würzburg, Würzburg, Germany. Supported by AbbVie Deutschland GmbH and Co. KG (formerly Abbott GmbH and Co. KG). F. Behrens, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; M. Koehm, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; H. Burkhardt, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; U. Arndt, MD, Rheumapraxis Hofheim; B.M. Wittig, MD, AbbVie Deutschland GmbH and Co. KG; G. Greger, PhD, AbbVie Deutschland GmbH and Co. KG; D. Thaçi, MD, Comprehensive Center of Inflammation Medicine, University Hospital Schleswig-Holstein Campus; E. Scharbatke, MD; H.P. Tony, MD, Schwerpunkt Rheumatologie/Klinische Immunologie Medizinische Klinik und Poliklinik II, Universität Würzburg. Dr. Behrens, Dr. Koehm, Dr. Arndt, Dr. Thaçi, Dr. Scharbatke, Dr. Tony, and Dr. Burkhardt have received speaker’s fees, research funding, or compensation for consultancies or board memberships from AbbVie Deutschland GmbH and Co. KG (formerly Abbott GmbH and Co. KG). Address correspondence to Dr. H. Burkhardt, Division of Rheumatology, Goethe University, Theodor-Stern-Kai 7, D60590 Frankfurt/Main, Germany. E-mail: Harald.Burkhardt@kgu.de. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication September 1, 2015.
Gerd Greger
From the Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main; Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP, Frankfurt am Main; Rheumapraxis Hofheim, Hofheim; AbbVie Deutschland GmbH and Co. KG, Wiesbaden; Comprehensive Center of Inflammation Medicine, University Hospital Schleswig-Holstein Campus, Luebeck; and Schwerpunkt Rheumatologie/Klinische Immunologie Medizinische Klinik und Poliklinik II, Universität Würzburg, Würzburg, Germany. Supported by AbbVie Deutschland GmbH and Co. KG (formerly Abbott GmbH and Co. KG). F. Behrens, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; M. Koehm, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; H. Burkhardt, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; U. Arndt, MD, Rheumapraxis Hofheim; B.M. Wittig, MD, AbbVie Deutschland GmbH and Co. KG; G. Greger, PhD, AbbVie Deutschland GmbH and Co. KG; D. Thaçi, MD, Comprehensive Center of Inflammation Medicine, University Hospital Schleswig-Holstein Campus; E. Scharbatke, MD; H.P. Tony, MD, Schwerpunkt Rheumatologie/Klinische Immunologie Medizinische Klinik und Poliklinik II, Universität Würzburg. Dr. Behrens, Dr. Koehm, Dr. Arndt, Dr. Thaçi, Dr. Scharbatke, Dr. Tony, and Dr. Burkhardt have received speaker’s fees, research funding, or compensation for consultancies or board memberships from AbbVie Deutschland GmbH and Co. KG (formerly Abbott GmbH and Co. KG). Address correspondence to Dr. H. Burkhardt, Division of Rheumatology, Goethe University, Theodor-Stern-Kai 7, D60590 Frankfurt/Main, Germany. E-mail: Harald.Burkhardt@kgu.de. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication September 1, 2015.
Diamant Thaçi
From the Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main; Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP, Frankfurt am Main; Rheumapraxis Hofheim, Hofheim; AbbVie Deutschland GmbH and Co. KG, Wiesbaden; Comprehensive Center of Inflammation Medicine, University Hospital Schleswig-Holstein Campus, Luebeck; and Schwerpunkt Rheumatologie/Klinische Immunologie Medizinische Klinik und Poliklinik II, Universität Würzburg, Würzburg, Germany. Supported by AbbVie Deutschland GmbH and Co. KG (formerly Abbott GmbH and Co. KG). F. Behrens, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; M. Koehm, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; H. Burkhardt, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; U. Arndt, MD, Rheumapraxis Hofheim; B.M. Wittig, MD, AbbVie Deutschland GmbH and Co. KG; G. Greger, PhD, AbbVie Deutschland GmbH and Co. KG; D. Thaçi, MD, Comprehensive Center of Inflammation Medicine, University Hospital Schleswig-Holstein Campus; E. Scharbatke, MD; H.P. Tony, MD, Schwerpunkt Rheumatologie/Klinische Immunologie Medizinische Klinik und Poliklinik II, Universität Würzburg. Dr. Behrens, Dr. Koehm, Dr. Arndt, Dr. Thaçi, Dr. Scharbatke, Dr. Tony, and Dr. Burkhardt have received speaker’s fees, research funding, or compensation for consultancies or board memberships from AbbVie Deutschland GmbH and Co. KG (formerly Abbott GmbH and Co. KG). Address correspondence to Dr. H. Burkhardt, Division of Rheumatology, Goethe University, Theodor-Stern-Kai 7, D60590 Frankfurt/Main, Germany. E-mail: Harald.Burkhardt@kgu.de. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication September 1, 2015.
Eva Scharbatke
From the Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main; Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP, Frankfurt am Main; Rheumapraxis Hofheim, Hofheim; AbbVie Deutschland GmbH and Co. KG, Wiesbaden; Comprehensive Center of Inflammation Medicine, University Hospital Schleswig-Holstein Campus, Luebeck; and Schwerpunkt Rheumatologie/Klinische Immunologie Medizinische Klinik und Poliklinik II, Universität Würzburg, Würzburg, Germany. Supported by AbbVie Deutschland GmbH and Co. KG (formerly Abbott GmbH and Co. KG). F. Behrens, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; M. Koehm, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; H. Burkhardt, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; U. Arndt, MD, Rheumapraxis Hofheim; B.M. Wittig, MD, AbbVie Deutschland GmbH and Co. KG; G. Greger, PhD, AbbVie Deutschland GmbH and Co. KG; D. Thaçi, MD, Comprehensive Center of Inflammation Medicine, University Hospital Schleswig-Holstein Campus; E. Scharbatke, MD; H.P. Tony, MD, Schwerpunkt Rheumatologie/Klinische Immunologie Medizinische Klinik und Poliklinik II, Universität Würzburg. Dr. Behrens, Dr. Koehm, Dr. Arndt, Dr. Thaçi, Dr. Scharbatke, Dr. Tony, and Dr. Burkhardt have received speaker’s fees, research funding, or compensation for consultancies or board memberships from AbbVie Deutschland GmbH and Co. KG (formerly Abbott GmbH and Co. KG). Address correspondence to Dr. H. Burkhardt, Division of Rheumatology, Goethe University, Theodor-Stern-Kai 7, D60590 Frankfurt/Main, Germany. E-mail: Harald.Burkhardt@kgu.de. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication September 1, 2015.
Hans-Peter Tony
From the Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main; Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP, Frankfurt am Main; Rheumapraxis Hofheim, Hofheim; AbbVie Deutschland GmbH and Co. KG, Wiesbaden; Comprehensive Center of Inflammation Medicine, University Hospital Schleswig-Holstein Campus, Luebeck; and Schwerpunkt Rheumatologie/Klinische Immunologie Medizinische Klinik und Poliklinik II, Universität Würzburg, Würzburg, Germany. Supported by AbbVie Deutschland GmbH and Co. KG (formerly Abbott GmbH and Co. KG). F. Behrens, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; M. Koehm, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; H. Burkhardt, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; U. Arndt, MD, Rheumapraxis Hofheim; B.M. Wittig, MD, AbbVie Deutschland GmbH and Co. KG; G. Greger, PhD, AbbVie Deutschland GmbH and Co. KG; D. Thaçi, MD, Comprehensive Center of Inflammation Medicine, University Hospital Schleswig-Holstein Campus; E. Scharbatke, MD; H.P. Tony, MD, Schwerpunkt Rheumatologie/Klinische Immunologie Medizinische Klinik und Poliklinik II, Universität Würzburg. Dr. Behrens, Dr. Koehm, Dr. Arndt, Dr. Thaçi, Dr. Scharbatke, Dr. Tony, and Dr. Burkhardt have received speaker’s fees, research funding, or compensation for consultancies or board memberships from AbbVie Deutschland GmbH and Co. KG (formerly Abbott GmbH and Co. KG). Address correspondence to Dr. H. Burkhardt, Division of Rheumatology, Goethe University, Theodor-Stern-Kai 7, D60590 Frankfurt/Main, Germany. E-mail: Harald.Burkhardt@kgu.de. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication September 1, 2015.
Harald Burkhardt
From the Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main; Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP, Frankfurt am Main; Rheumapraxis Hofheim, Hofheim; AbbVie Deutschland GmbH and Co. KG, Wiesbaden; Comprehensive Center of Inflammation Medicine, University Hospital Schleswig-Holstein Campus, Luebeck; and Schwerpunkt Rheumatologie/Klinische Immunologie Medizinische Klinik und Poliklinik II, Universität Würzburg, Würzburg, Germany. Supported by AbbVie Deutschland GmbH and Co. KG (formerly Abbott GmbH and Co. KG). F. Behrens, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; M. Koehm, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; H. Burkhardt, MD, Division of Rheumatology, University Hospital Frankfurt, Goethe University, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP; U. Arndt, MD, Rheumapraxis Hofheim; B.M. Wittig, MD, AbbVie Deutschland GmbH and Co. KG; G. Greger, PhD, AbbVie Deutschland GmbH and Co. KG; D. Thaçi, MD, Comprehensive Center of Inflammation Medicine, University Hospital Schleswig-Holstein Campus; E. Scharbatke, MD; H.P. Tony, MD, Schwerpunkt Rheumatologie/Klinische Immunologie Medizinische Klinik und Poliklinik II, Universität Würzburg. Dr. Behrens, Dr. Koehm, Dr. Arndt, Dr. Thaçi, Dr. Scharbatke, Dr. Tony, and Dr. Burkhardt have received speaker’s fees, research funding, or compensation for consultancies or board memberships from AbbVie Deutschland GmbH and Co. KG (formerly Abbott GmbH and Co. KG). Address correspondence to Dr. H. Burkhardt, Division of Rheumatology, Goethe University, Theodor-Stern-Kai 7, D60590 Frankfurt/Main, Germany. E-mail: Harald.Burkhardt@kgu.de. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication September 1, 2015.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Does Concomitant Methotrexate with Adalimumab Influence Treatment Outcomes in Patients with Psoriatic Arthritis? Data from a Large Observational Study
Frank Behrens, Michaela Koehm, Uta Arndt, Bianca M. Wittig, Gerd Greger, Diamant Thaçi, Eva Scharbatke, Hans-Peter Tony, Harald Burkhardt
The Journal of Rheumatology Dec 2015, jrheum.141596; DOI: 10.3899/jrheum.141596
Does Concomitant Methotrexate with Adalimumab Influence Treatment Outcomes in Patients with Psoriatic Arthritis? Data from a Large Observational Study
Frank Behrens, Michaela Koehm, Uta Arndt, Bianca M. Wittig, Gerd Greger, Diamant Thaçi, Eva Scharbatke, Hans-Peter Tony, Harald Burkhardt
The Journal of Rheumatology Dec 2015, jrheum.141596; DOI: 10.3899/jrheum.141596